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CHAPTER I 
 
INTRODUCTION 
 
 
Background 
Mitral Valve Anatomy and Function 
The mitral valve (MV) is a bi-leaflet heart valve which sits between the left atrium 
and left ventricle of the heart. The complex anatomy of the MV consists of five primary 
components: (1) the annulus, a fibrous ring of tissue located at the base of the atrium, 
(2) two leaflets, consisting of the anterior and posterior leaflets, (3) commissures, which 
are the sites of separation between the leaflets, (4) chordae tendineae, which act to 
tether the free edges of the MV leaflets to the ventricular wall, and (5) the papillary 
muscles, the sites of chordae tendineae attachment (Fig. 1). The anterior leaflet is the 
larger of the two leaflets, and is approximately twice the height of the posterior leaflet.14 
The posterior leaflet consists of three distinct scallops, with the central scallop being the 
largest in approximately 90% of normal hearts.14 
During normal functioning of the heart, the MV opens during diastole in order to 
allow passive filling of the left ventricle. During systole, when the heart is pumping blood 
to the systemic circulation of the body, the MV is closed and must resist large pressures 
(>120 mmHg) exerted on it to prevent reverse blood flow. Abnormalities of any of the 
primary components of the MV, as well as problems associated with left atrial or left 
ventricular dysfunction, can lead to malfunctioning of the MV,32 and the type and severity 
of the diseased structure determines whether surgical techniques are needed to treat the 
defect. 
 
 
2 
 
 
Figure 1. Mitral Valve Anatomy. A) Anatomy of the mitral valve, indicating the five 
major strutural components: the annulus, leaflets, commisures, chordae tendineae, and 
papillary muscles. B) A comparison of the larger, anterior leaflet and the three scallops 
that form the posterior leaflet. Figure A from Otto.35 
 
 
Mitral Regurgitation and Mitral Valve Prolapse 
 Problems associated with the MV result in a “leaky” valve, in which reverse blood 
flow occurs across the MV during systole. This is termed mitral regurgitation (MR), and 
severe cases of MR can lead to left ventricular dysfunction and congestive heart 
failure.41 Poor leaflet coaptation is the endpoint through which MR occurs, and one 
specific syndrome is termed mitral valve prolapse (MVP), which affects about 2% of the 
anterior
posterior
A
B
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population13 and is defined as superior displacement greater than 2 mm of one or both 
leaflets into the atrium during systole (Fig. 2).26 MVP can be characterized by any of the 
following conditions: thickened and redundant leaflets, annular dilatation, and thickened 
and elongated chordae tendineae.14 The severity and underlying cause of MR due to 
MVP dictates the type of treatment administered, and open-chest replacement or repair 
is the current gold standard for treatment of moderate-to-severe and severe MR in 
patients with symptoms of left ventricular dysfunction.10 This represents a significant 
problem in older patients who are more at-risk when undergoing invasive surgical 
procedures, a population that is currently growing, as the population of Americans aged 
65+ is estimated to more than double – from 34 to 79 million – over the next 50 years.45  
 
Figure 2. Mitral Valve Prolapse. Superior displacement of mitral valves into the left 
atrium during systole results in mitral regurgitation. Mitral valve prolapse can affect one 
or both leaflets, and is shown affecting the anterior leaflet above. Figure from Medline.1 
 
 
MVP Due to Degenerative MR 
 The most common cause of MVP is due to a degenerative disease of the MV 
apparatus termed myxomatous MV disease, and an estimated 1% to 2% of the 
population has some form of myxomatous MV disease.9 Additionally, approximately 
6.5% to 9% of all diagnosed cases of MVP result in severe MR,8,12 requiring treatment to 
improve quality of life. While myxomatous disease is currently not well understood at the 
Atrium
Ventricle
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cellular and molecular levels,9 it is well characterized at the tissue and functional levels. 
Histology of autopsied leaflets with myxomatous disease indicates disrupted and 
fragmented collagen architecture with a larger than normal layer of proteoglycans (Fig. 
3).37 These tissue level changes cause MV leaflets with myxomatous disease to become 
thickened and enlarged, and the redundant tissue of these leaflets leads to poor leaflet 
coaptation and MR. 
 
Figure 3. Histology of Normal and Myxomatous Mitral Valve Leaflets. Histology 
reveals fragmented collagen architecture and an increased quantity of proteoglycans in 
the myxomatous leaflet, shown left. Figure from Rabkin et al.37 
 
 
Morphologic analysis of myxomatous MVs has shown a greater than two-fold 
increase in valve surface area, due to significant increases in both the anterior and 
posterior leaflet surface areas.25 Additionally, the structural elements of the MV – 
collagen, elastin, and proteoglycans – constitute approximately 85-95% of leaflet dry 
weight,7,28 indicating that alteration of these components will significantly affect leaflet 
mechanical properties. Myxomatous leaflets have previously been shown to be more 
extensible and less than half as strong as normal leaflets, further contributing to leaflet 
prolapse and MR.5 Similar enlargement and extensibility changes can also occur in the 
chordae tendineae, in which the chords become thickened and elongated, leading to 
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leaflet billowing into the atrium during systole. It is the combination of (1) increased 
surface area and (2) increased mechanical compliance that leads to prolapse of 
myxomatous leaflets during systole. Due to the redundant leaflet surface area present in 
enlarged, myxomatous leaflets, the coaptation surface, or closing edge, cannot form a 
smooth seal, leading to MR (Fig. 4). Depending on the severity and extent of the 
disease, both the MV leaflets and chords can be affected separately or in combination. 
Thus, treatments to repair the MV to mitigate MR due to myxomatous disease are 
focused on improving leaflet coaptation via repair of the leaflets or alteration of the 
chordae tendineae. 
 
Figure 4. Mitral Valve Closing Edge. The closing edge of the MV leaflet lies close to 
the free edge of the leaflet, just below the clear zone (CZ). Figure from Hurst’s the 
Heart.14 
 
 
Repair of the MV Due to Degenerative MR 
 The current standard in long-term treatment of MVP due to myxomatous disease 
is open-chest surgical repair or replacement, depending on the severity and structure 
affected. To date, there are no known therapies that directly affect the disease process 
in the MV apparatus.35 Repair of the MV is generally preferred over replacement due to 
lower rates of thromboembolism, resistance to endocarditis, the avoidance of a 
A B
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prosthetic valve and associated long-term anticoagulation therapy, as well as the 
excellent durability of repairs – as long as 25 years – compared to valve replacement.9 
The benefit of MV repair is that it preserves the sub-valvular apparatus, consisting of the 
chords and papillary muscles, as removal of these structures has been associated with 
detrimental effects on left ventricular shape and performance.19,46 However, recent rates 
of repair in those who required MV surgery were as low as 44% in the United States,39 
indicating that the complexity of valve repair makes treatment difficult, and more 
improved techniques will be necessary to improve repair rates.  
 Recently, less-invasive, percutaneous techniques have been in development to 
treat MVP. Percutaneous techniques are often preferred over surgical procedures 
because they have been shown to reduce the need for blood transfusions, decrease 
rates of infection, and reduce recovery time.15,43 These benefits have the potential to 
reduce procedure cost and recovery time dramatically. Currently, the MitraClip (Abbot 
Laboratories) is the most developed of the percutaneous techniques in clinical trials.4,11 
The MitraClip is a percutaneous variation of the Alfieri edge-to-edge repair,3 in which the 
two leaflets of the MV are sutured together, forming a double-orifice. The MitraClip 
allows this procedure to be performed percutaneously with the placement of a clip to 
pinch together the anterior and posterior leaflets. A recent comparison to open-heart MV 
repair indicated that while the rate of major adverse clinical events was significantly 
lower with the percutaneous treatment, the efficacy of treatment was also significantly 
lower than the open-heart repair.10 Additionally, this procedure requires permanent 
placement of a foreign body and the long-term fluid dynamics of the double-orifice MV 
are poorly understood.23 In combination with the results from the clinical trial, this 
indicates that there is still a need for additional percutaneous procedures that can 
reduce MR and preserve the MV apparatus.  
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Percutaneous Application of Radiofrequency Ablation to Treat MVP 
 One potential percutaneous treatment option for MVP is with radiofrequency 
ablation (RF), an established technique for treating cardiac arrhythmias that has been 
around since the mid-1980s. RF ablation utilizes electrical signals at around 300-700 
kHz in order to generate resistive heating for ablation of tissue. It is dependent on power, 
electrode-tissue interface temperature, electrode size, and contact pressure.21 The 
target of RF ablation is the collagen architecture of the MV leaflets, which contributes to 
much of the strength and mechanical properties of the tissue.18 In MV leaflets, collagen 
is preferentially aligned with the circumference of the MV annulus, which causes an 
anisotropic loading response in normal leaflets (Fig. 5).  
 
Figure 5. Anisotropic Response of MV Leaflets. A) Collagen is preferentially aligned 
with the circumferential direction in MV leaflets. B) Due to this collagen alignment, MV 
leaflets are more stiff in the circumferential direction than the radial direction. 
 
 
This collagen alignment greatly affects the response of MV tissue to application of RF 
energy. Previously, the triple-helical structure of collagen has been shown to denature 
and contract when heated to greater than 65°C.42 Following treatment with RF ablation, 
collagenous tissues undergo shortening in the direction of collagen alignment. 
Additionally, transmission electron microscopy has shown an increase in collagen fiber 
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diameter and a loss of cross-striations with increasing application of RF power.33 Prior 
treatment of porcine MV leaflets with RF ablation in vitro has demonstrated directional 
length changes that are dependent on RF power (Fig. 6).36 Therefore, the goal of using 
RF ablation to treat myxomatous MV leaflets is to induce permanent changes in leaflet 
geometry via resistive heating of collagen and subsequent shortening.  
 
Figure 6. MV Leaflet Geometry Following RF Ablation. Change in length in the radial 
(grey bars) and circumferential (black bars) following 5, 10, 15, and 25 W of RF ablation. 
Figure from Price et al.36 
 
 
 The history of utilizing percutaneous application of RF ablation to alter the MV 
apparatus is brief and began with two animal studies published in 2008. The first of 
these studies used the QuantumCor device, which uses a circular RF ablation probe to 
reduce the MV annulus diameter and approximates an annuloplasty procedure used to 
treat some cases of MVP.20 Use of the QuantumCor device in 16 sheep reduced the 
anterior-posterior dimension of the MV annulus by more than 20%, and these changes 
remained durable for the duration of the 180-day study, with tissue fibrosis and necrosis 
present at the endpoint.16 However, this study was performed in normal sheep, with little 
to no traces of MR. The second study used a standard RF ablation catheter to apply RF 
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energy directly to MV leaflets in order to reduce leaflet size and alter biomechanical 
properties and was performed on two separate treatment groups.43 The first group used 
RF ablation to directly treat myxomatous leaflets in beagles under open-heart surgery, 
resulting in 40-60% reduction in post-ablation MR. The second group applied RF 
ablation percutaneously to healthy beagles, until structural damage was observed, and 
monitored the durability of the changes for 6 weeks. The result of this study indicated 
that these changes are potentially durable long-term. While these results indicate that 
RF ablation is a feasible strategy for reducing MR in myxomatous MVs, percutaneous 
application of RF energy was difficult, due to the continuous movement of the MV 
leaflets. Thus, a strategy is needed to anchor the RF catheter tip, in order to move 
reliably apply RF energy directly to the leaflets themselves. 
 
Cryo-Anchoring for MV Attachment 
 To date, no device has been published with the ability to temporarily anchor a 
catheter to a moving MV. In order to enable more reliable application of RF energy to 
MV leaflets, the requirements for an anchoring device are to enable reversible 
attachment to either the posterior or anterior MV leaflet, depending on the desired 
ablation target. Additionally, anchoring to the chords for RF ablation represents another 
potential target. Cryoablation is one technology that has been used to percutaneously 
treat cardiac arrhythmias since 1999,24 which uses pressurized liquid nitrogen to cool a 
catheter tip to temperatures as low as -80°C. A technique termed cryo-mapping was 
developed for use with these cryoablation catheters, which cools the catheter tip to 
temperatures as low as -30°C to temporarily attach the catheter and induce 
electrophysiological changes in cardiac tissues.21 This is performed with minimal cellular 
damage and little effect on the structural properties of the tissue.40 Given the negligible 
amount of tissue damage induced at temperatures as low as -30°C, and the temporary, 
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reversible tissue attachment that can be created, this cryo-anchoring technique 
represents one potential strategy to maintain attachment to moving MV leaflets. 
 
 
Objective 
 The objective of this work was to develop and test a prototype catheter to 
determine the feasibility of radiofrequency ablation with cryo-anchoring in percutaneous 
treatment of mitral valve prolapse. One common cause of mitral valve prolapse is 
thickened and enlarged leaflets which billow back into the left atrium during valve 
closure, causing mitral regurgitation. The goal of this treatment strategy is to reduce 
mitral valve leaflet size via resistive heating with radiofrequency ablation in order to 
improve leaflet coaptation and reduce mitral regurgitation. However, in order to perform 
this procedure in vivo, a method is needed to provide attachment to moving mitral valve 
leaflets during administration of radiofrequency energy. Cryo-anchoring, which functions 
similarly to cryoablation, is one technique which can maintain this attachment. Cryo-
anchoring utilizes liquid nitrogen to generate sub-freezing temperatures on the surface of 
a catheter tip, which provides adherence to tissues such as the mitral valve. Thus, the 
two techniques, radiofrequency ablation and cryo-anchoring, directly oppose each other 
and must be balanced in order to provide optimal treatment of mitral valve prolapse. The 
study that follows verifies the feasibility of utilizing these two techniques in close 
proximity, and provides an estimate for the amount of radiofrequency energy required to 
alter mitral valve leaflet geometry and biomechanics in the presence of cryo-anchoring. 
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Specific Aims 
1. Develop a catheter prototype that contains both a cryogenically cooled anchoring 
element (cryo-anchor) and a radiofrequency ablation electrode on the same 
catheter tip, capable of treating mitral valve leaflets in vitro 
2. Quantify the effects of radiofrequency ablation treatment with cryo-anchoring on 
the geometry and biomechanical response of mitral valve leaflets. 
3. Determine the mitral valve leaflet temperature distribution resulting from 
treatment with combined radiofrequency ablation and cryo-anchoring 
4. Determine the attachment strength of the cryo-anchor to stationary mitral valve 
leaflets, both with and without radiofrequency ablation 
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CHAPTER II 
 
MANUSCRIPT: DEVELOPMENT OF A SIMULTANEOUS CRYO-ANCHORING AND 
RADIOFREQUENCY ABLATION CATHETER FOR PERCUTANEOUS TREATMENT OF MITRAL VALVE 
PROLAPSE 
 
 
Abstract 
Mitral valve prolapse is one subtype of mitral valve disease and is often 
characterized by enlarged leaflets that are thickened and have disrupted collagen 
architecture. The increased surface area of myxomatous leaflets with mitral valve 
prolapse leads to mitral regurgitation, and there is need for percutaneous treatment 
options that avoid open-chest surgery. Radiofrequency ablation is one potential therapy 
in which resistive heating can be used to reduce leaflet size via collagen contracture. 
One challenge of using radiofrequency ablation to percutaneously treat mitral valve 
prolapse is maintaining contact between the radiofrequency ablation catheter tip and a 
functioning mitral valve leaflet. To meet this challenge, we have developed a 
radiofrequency ablation catheter with a cryogenic anchor for attachment to leaflets in 
order to apply radiofrequency ablation. We demonstrate the effectiveness of the dual-
energy catheter in vitro by examining changes in leaflet biaxial compliance, thermal 
distribution with infrared imaging, and cryogenic anchor strength. We report that 1250 J 
of radiofrequency energy with cryo-anchoring reduced the determinant of the 
deformation gradient tensor at systolic loading by 23%. Infrared imaging revealed 
distinct regions of cryo-anchoring and tissue ablation, demonstrating that the two 
modalities do not counteract one another. Finally, cryogenic anchor strength to the 
leaflet was reduced but still robust during the application of radiofrequency energy. 
These results indicate that a catheter having combined radiofrequency ablation and 
cryo-anchoring provides a novel percutaneous treatment strategy for mitral valve 
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prolapse and may also be useful for other percutaneous procedures where anchored 
ablation would provide more precise spatial control. 
 
Key Terms 
Heart valve mechanics, mitral valve prolapse, radiofrequency ablation, cryo-ablation, 
infrared thermal imaging 
 
Introduction 
Mitral valve (MV) disease is the most common form of heart valve disease, 
occurring in approximately 2% of the population and resulting in 43,000 open-chest 
surgical procedures every year.13 MV prolapse (MVP) is one subtype of the disease and 
is characterized by superior displacement of one or both leaflets into the left atrium, 
resulting in mitral regurgitation (MR). One common cause of MVP is myxomatous mitral 
valve disease, which is characterized by thickened and enlarged leaflets, disrupted and 
compromised collagen architecture, and an increased quantity of proteoglycans. The 
etiology is unknown at this time.37 
The current gold standard to correct MVP is open-chest surgical valve repair or 
replacement, which is highly undesirable for elderly patients. In the past decade, 
percutaneous treatment of MV disease has received a great deal of interest.6,9,31 
Specifically, the MitraClip4,11 (Abbott Laboratories) is one technique undergoing clinical 
trials and is a percutaneous variation of the Alfieri edge-to-edge technique,3 which 
creates a double orifice valve by fixing together the free edges of the anterior and 
posterior leaflets. The MitraClip has been assessed in the EVEREST II clinical trial and 
was found to have a 55% rate of primary end point efficacy at 12 months, which included 
freedom from grade 3+ or 4+ MR, freedom from death, and freedom from surgery for MV 
dysfunction.10 Additionally, major adverse clinical events occurred at a rate of only 15% 
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in the percutaneous-repair group at 30 days, compared with 48% of patients in the 
surgery group. While the reduced complication rate indicates that percutaneous 
strategies may represent a safer alternative to open-chest surgery, the end point efficacy 
indicates that there remains room for improvement. Therefore, we believe that there is a 
need for additional percutaneous options to treat MVP that preserve the MV apparatus 
and restore normal fluid mechanics.  
One potential percutaneous treatment strategy for myxomatous MVP is the use 
of radiofrequency (RF) ablation to reduce MV leaflet size to reduce MR. Due to the 
increased size of myxomatous leaflets, they fail to properly coapt during systole, and this 
redundancy of excess leaflet tissue provides an opening for regurgitant flow. By reducing 
leaflet size, coaptation could improve and thereby reduce MR. RF ablation generates 
thermal lesions via resistive heating of tissue and is dependent on power, interface 
temperature, electrode size, and contact pressure.21 For our purposes, the target of RF 
ablation is the disrupted or distended collagen architecture of the MV leaflets; collagen 
has been shown to denature and contract when heated to temperatures greater than 
65°C.42 Using biaxial mechanical testing, we have demonstrated that RF ablation 
effectively reduces MV leaflet geometry and alters biomechanical compliance in vitro.36 
Previously, RF ablation treatment of myxomatous MVP has been shown to be 
feasible in a surgical canine model in which an acute in vivo study was performed on 
beagles with MR under open-heart surgery, demonstrating a mean 49.6% reduction in 
post-ablation MR.43 Additionally, a chronic in vivo study was performed on healthy 
beagles to assess the ability to apply RF energy percutaneously and to assess the 
durability of the procedure at 6 weeks. An average of 22 applications of RF ablation for 
60 seconds at an average power of 58 W was required to induce structural alteration of 
the leaflets, and alterations were found to be durable 6 weeks later. For comparison, 4 
applications of RF ablation for approximately 40 seconds at a power of 16 W were 
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required to reduce MR in the acute in vivo study. These results indicate that: (1) RF 
ablation is a feasible technique for reducing MR, (2) the alterations due to RF ablation 
remain durable, although the effects on valvular tissues after 6 weeks are not known, 
and (3) more RF energy is required to induce structural alteration of MV leaflets when 
applying RF energy percutaneously due to heat dissipation to the surrounding blood.  
The primary explanation for the increased number of RF ablation applications in the 
percutaneous case is that poor contact exists between the RF electrode on the catheter 
tip and the surface of the moving MV leaflet. The result of this is that RF energy may 
have been delivered entirely into the blood or into the surrounding myocardium. 
Therefore, to reduce misguided application of RF energy and improve delivery directly 
into the MV leaflet tissue, a stability technique is needed to physically anchor the 
catheter tip to the leaflet surface.   
One possible method of maintaining contact between the RF ablation catheter tip 
and the moving MV leaflet is using a catheter with a cryogenically cooled anchoring 
element, or a cryo-anchor. This technique works similarly to cryo-ablation, which uses 
pressurized liquid nitrogen to cool a catheter tip to temperatures as low as -80°C and 
has been utilized since 1999 as an alternative for treating cardiac arrhythmias.24 Cryo-
ablation is generally less destructive than RF ablation and has previously been shown to 
maintain the extracellular collagen matrix, without collagen denaturation or contracture 
related to thermal effects.40 Further, permanent damage to myocardial tissues due to 
cryo-ablation has been shown to occur only at temperatures below -30°C,21 making this 
temperature an excellent target for use in a cryo-anchor. While cryo-anchoring is used 
here as a method to adhere to MV leaflets, it may have broader applications in use as a 
stability technique for a variety of percutaneous procedures. For example, treatments 
that require the use of RF ablation in dynamic environments, such as treatment of 
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cardiac arrhythmias, could potentially benefit from using cryo-anchoring for catheter 
stability. 
The purpose of this study was to determine the feasibility of using cryo-anchoring 
and RF ablation on the same catheter tip and to quantify the biomechanical and 
thermodynamic effects of RF ablation on porcine MV leaflets. We hypothesized that an 
RF ablation catheter that utilizes a cryo-anchor will effectively adhere to and alter MV 
leaflet geometry and compliance, reducing MV leaflet size at maximum systolic load. To 
test this hypothesis, we developed a catheter prototype containing both a cryo-anchor 
for attachment and stability and an RF electrode for ablation. To investigate the effects 
of using cryogenic temperatures and resistive heating in close proximity, we quantified 
changes in biaxial mechanical compliance of MV leaflets and used infrared (IR) thermal 
imaging to discern distinct thermal regions within the tissue. We also quantified the 
anchor strength of the cryo-anchor both with and without RF ablation. These data 
support our hypothesis that simultaneous cryo-anchoring and RF ablation effectively 
reduces MV leaflet size and compliance, while further demonstrating that cryo-anchoring 
and RF ablation can function effectively in close proximity on a single catheter tip.  
 
Materials and Methods 
Catheter Prototype 
A 4 mm (12 French) diameter catheter prototype was developed containing both 
a cryogenically cooled anchor (cryo-anchor) and an RF ablation electrode (Figs. 7A and 
7B). The cryo-anchor and RF electrode reside in-line on the catheter shaft and are 
separated by a 1 mm spacer, with the cryo-anchor on the most distal point of the 
catheter. Both the cryo-anchor and RF electrode are constructed out of hollow copper 
rod and are approximately 1.9 mm in length. The cryo-anchor is thermally connected via 
a solder joint to an inner copper rod containing a lumen which allows liquid nitrogen  
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Figure 7. RF and Cryo-Anchoring Catheter Design. (A) Solid model cut-away of the 
catheter prototype design, indicating the relative positions of the cryo-anchor, insulating 
spacer, and RF electrode. (B) Catheter prototype tip used for all treatments of tissue 
(scale bar = 1/8”). (C) Flow chart representation of the control system used to integrate 
and synchronize cryo-anchoring with RF ablation for treatment of tissue. (D) Sequence 
programmed into the controller for performing RF ablation treatments with cryo-
anchoring. Note that liquid nitrogen delivery to the catheter tip begins prior to RF ablation 
in order to first anchor the catheter tip to the tissue surface. RF power is represented as 
being applied instantaneously; however, it took ~3 s for RF power to reach target power. 
Final RF energy delivery (J=Joules) is indicated on the plot and represents total energy 
delivery of each treatment. 
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delivery. Teflon is used to insulate the RF electrode from the cryo-anchor and inner 
copper rod, and a thermocouple attached to the outer surface of the cryo-anchor records 
the temperature at the anchor-tissue interface. RF ablation is performed with an Osypka 
HAT 300 generator, capable of delivering a 500 kHz electrical signal at powers of up to 
50 W to the RF electrode on the catheter tip. Liquid nitrogen is contained inside a 
handheld canister (Cry-Ac, Brymill Cryogenic Systems) and delivered to the catheter tip 
under vacuum by an inner lumen housed inside the catheter.  
Control of RF ablation and liquid nitrogen delivery is performed via custom built 
control electronics for synchronization and repeatability (Fig. 7C). Liquid nitrogen flow 
control is binary, and a servo motor is used to switch flow on and off. The sequence 
used for liquid nitrogen flow was developed to anchor the catheter tip to the tissue 
sample prior to RF ablation and to maintain anchoring throughout the ablation (Fig. 7D). 
Control of the RF generator was performed by interfacing with the footswitch port on the 
generator, with air flow controlled by a solenoid valve and control electronics. For each 
ablation, one of three RF protocols was utilized at 25, 45, or 50 W of power for 15, 20, or 
30 s, respectively (Fig. 7D). Due to the time required for the RF generator to increase 
the power to the desired set-point (~3 s), the total energy output was lower than that 
produced by the product of time and power (Joules = W s). The final energy delivery to 
the tissue, as recorded by the generator for each of the 25, 45 and 50 W ablations, was 
350, 850, and 1250 Joules (J), respectively.  
 
Tissue Preparation 
Healthy porcine MV leaflets were obtained from a local abattoir (Hampton Meat 
Processing, Hopkinsville, KY), excised on-site, and frozen in phosphate buffered saline 
(PBS) at -20°C until testing. Anterior leaflets were chosen for the biomechanical and 
thermal imaging studies due to their larger and more continuous surface area compared 
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to posterior leaflets, although it is noted that posterior leaflets are more often affected by 
MVP.9 The center portion of the leaflets were used and trimmed into rectangular sections 
(Fig. 8A) approximately 12 mm in the radial direction and 15 mm in the circumferential 
direction. The center portion was used as it experiences the most homogenous strains 
during MV closure.38 For the anchor strength study, posterior leaflets were used for 
testing.  
 
Figure 8. Experimental Design. (A) Mitral valve anatomy with marker placement and 
biaxial testing device with leaflet tissue in place. (B) Set-up for full thickness thermal 
imaging. The IR camera is placed below in order to measure the temperature distribution 
throughout the entire surface of the tissue. An IR window allows transmission of IR 
wavelengths for unimpeded temperature measurement. (C) Set-up for measurement of 
anchor strength of the cryo-anchor. Leaflets are clamped into the load cell assembly, 
and the maximum load is recorded. 
 
 
 
Biaxial Mechanical Testing 
Biomechanical analysis was performed using a custom-designed biaxial 
mechanical testing device (Fig. 8A).36 Samples were loaded in each direction up to a 
membrane tension comparable to that experienced by the leaflet during systole (120 
mmHg ≈ 90 N/m of membrane tension), and all testing was performed with samples fully 
submerged in PBS at 37°C. Prior to testing, each sample was pre-conditioned over ten 
loading cycles to 90 N/m with a 15 s rise time. Following pre-conditioning, a marker 
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reference was recorded and used as the unloaded state. Samples were then tested for 
ten cycles with a 15 s rise time to 90 N/m in order to determine untreated compliance. 
Stress-strain behavior has been found to be independent of loading rate for cycles with 
rise times of up to 15 s, thus tissues were not loaded at physiologic rates 17. 
After determining leaflet biomechanical properties, samples were loaded to 10 
N/m and subjected to one of the following four treatments with the catheter prototype. In 
order to determine the biomechanical effects of the cryo-anchor alone, samples were 
kept in contact with the cryo-anchor for 30 s at approximately -20 to -30°C (n = 3). To 
test the combined effects of cryo-anchoring and RF ablation, tissues were subjected to 
one of three treatment groups (n = 5) as described earlier and shown in Fig. 7D. During 
treatment, the fluid level in the bath was lowered to just below the surface of the sample 
in order to ensure that maximal energy transfer was through the tissue. By performing 
treatment such that all RF energy must pass through the sample, the amount of RF 
energy required to invoke the recorded biomechanical changes can be determined. The 
alternative is to completely submerge leaflets during treatment, but this provides a very 
low resistive path to ground, which bypasses the target tissue via direct conduction 
through the PBS bath. Four ground electrodes were placed in the bath, approximately 13 
cm away from the tissue, to complete the electrical circuit for RF ablation. Following 
treatment, samples were returned to their unloaded state, a new marker reference was 
recorded to determine changes in unloaded geometry, and samples were loaded for ten 
cycles to 90 N/m. All data reported is from the tenth loading cycle of each experiment.  
All analysis of biaxial mechanical data was performed using MATLAB 
(Mathworks). Marker positions recorded just prior to loading were used to determine 
geometric changes of the unloaded tissues due to treatment with the catheter prototype. 
Unloaded marker area was calculated as the area enclosed by the polygon connecting 
the four markers. Additionally, the percent change in the determinant of the deformation 
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gradient tensor, F (% change in det(F)) was used to provide a quantitative assessment 
of the biomechanical changes of the tissue at maximum systolic load. The determinant 
of F is the ratio of the deformed marker area to the marker area of the reference state, 
where: 
 
F11 and F22 represent the stretch ratios in the circumferential and radial 
directions, respectively, and κ1 and κ2 provide a measure of shear. det(F) was 
determined at 90 N/m before and after treatment, and the unloaded marker reference 
state recorded just after pre-conditioning was used for all calculations. Because the 
same marker reference state is used to determine F in both the untreated and treated 
conditions, % change in det(F) provides a direct comparison of systolic leaflet 
deformation before and after treatment. Therefore, we refer to % change in det(F) at 90 
N/m as % change in areal systolic deformation. In addition to reporting changes in det(F) 
due to treatment, we also report % change in axial systolic deformations which are 
changes in F11 and F22 at 90 N/m. For a more complete description of the calculation of F 
from biaxial mechanical testing, see Humphrey.22 
 
Infrared Thermal Imaging 
Thermal imaging of simultaneous cryo-anchoring and RF ablation was performed 
using an IR camera (ThermoVision A20M, FLIR Systems) with a measurement range of 
-20°C to 250°C and accuracy of ±2°C. Previous studies have used IR imaging to identify 
the lethal isotherm of RF lesions.27,44 Leaflets were imaged in a custom built bath, and 
the camera was placed below the bath for imaging of full thickness changes in 
temperature distribution (Fig. 8B). An IR window (IR Material Window, Edmund Optics 
Inc.) was placed at the bottom of the bath to allow imaging through the bottom surface 
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by allowing transmission of IR wavelengths. Prior to treatment, an image was taken of a 
calibration phantom to determine the x and y distance scales. Testing was performed in 
PBS at room temperature, and the fluid level was lowered to just below the top surface 
of the tissue to allow maximal energy transfer through the leaflet. Four ground electrodes 
were placed in the bath in a circular pattern, each approximately 13 cm from the center 
of the leaflet. During ablation, a non-conductive plate was placed over the leaflet in order 
to maintain contact of the entire leaflet surface with the IR window. This was done to 
ensure that the temperatures measured were of the leaflet itself and not the fluid 
between the leaflet and IR window. All samples were then treated using one of the 
ablation sequences in Fig. 7D (n = 3 for each of the 350, 850, and 1250 J sequences), 
and images of the treatment were recorded at 1 Hz beginning at the onset of RF ablation 
using ThermaCAM Researcher software and synchronized with the ablation sequence 
using the control electronics. Images were then analyzed in MATLAB to produce thermal 
contour plots of the tissue. Additionally, the area of tissue heated to > 65°C was 
quantified in order to provide a measure of the extent of thermal contracture of the 
extracellular matrix collagen, and the tissue area < 0ºC was also quantified to provide an 
estimate of the attachment area of the catheter prototype. 
 
Anchor Strength 
In order to assess the anchor strength of the cryo-anchor both with and without 
RF ablation, a submersible load cell was used (Model 31 Mid, Honeywell). Posterior MV 
leaflets were clamped onto the load cell assembly and completely submersed in PBS at 
37°C (Fig. 8C). Leaflets were completely submersed during treatment in order to test the 
anchor strength of the cryo-anchor in an environment that more closely mimics the in 
vivo case. The output from the load cell was amplified using a custom built amplifier 
circuit and read into LabView using a data acquisition card (NI 9205, National 
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Instruments). Anchor strength was tested at one of two protocols (n = 5 for each 
protocol). For the “Cryo Only” protocol, liquid nitrogen was pumped under vacuum to the 
catheter tip continuously for 10 s, and the catheter was then immediately pulled from the 
leaflet surface until separation. To determine the loss of anchor strength resulting from 
application of RF energy, the “RF + Cryo” protocol consisted of 5 s of continuous liquid 
nitrogen delivery, followed by 10 s of RF ablation at 50 W with continuous liquid nitrogen 
delivery. The catheter was then pulled away from the leaflet surface until separation. In 
both cases, the maximum load during separation was recorded. Maximum load was 
converted to anchor strength by dividing the load by 0.12 cm2, the approximate area of 
the cryo-anchor in contact with the tissue. 
 
Statistics 
Data are presented as mean ± SE. To analyze significance of changes due to 
combined RF ablation and cryo-anchoring for the biomechanical and anchor strength 
studies, data were analyzed using a one way ANOVA (α = 0.05) for multiple pair wise 
comparison (Holm-Sidak method).  
 
Results 
Tissue Geometry and Compliance 
Prior to treatment, leaflets displayed a typical, anisotropic mechanical response 
to loading,18 with the radial direction much more compliant than the circumferential 
direction (Figs. 9A and 9B). This is due to collagen fibers being preferentially aligned in 
the circumferential direction. Following 30 s of cryo-anchoring, MV leaflets experienced 
negligible changes in geometry and mechanical response (Fig 9A). However, after 1250 
J of RF ablation with cryo-anchoring, leaflets underwent significant changes. In the 
circumferential direction, changes in systolic deformation were attributable primarily to 
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shrinkage of the tissue, as indicated by a large shift in stretch ratio in the unloaded state 
(membrane tension = 0 N/m), while the radial direction underwent a decrease in systolic 
deformation with little geometric changes.  
 
Figure 9. Biaxial Mechanical Response. Biaxial, membrane tension vs. stretch ratio 
following 30 s of cryo-anchoring without RF ablation (A) and with 1250 J of RF ablation 
(B). (C) % Change in unloaded marker area for each treatment group (0 J represents 
cryo-anchoring without RF ablation). % Change in unloaded marker lengths (D), areal 
systolic deformation (E), and axial systolic deformation (F) for each treatment group. + 
Significant decrease vs. 0 J (p<0.001) and ** significant decrease vs. 850 J (p<0.05). 
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There was a consistent trend of decreasing marker area with increasing RF 
energy (Fig. 9C), due primarily to decreases in length in the circumferential direction 
(Fig. 9D). Change in systolic deformation was analyzed at maximum load, 90 N/m (Figs. 
9E and 9F), with all deformations referenced to the marker reference state recorded just 
after pre-conditioning. Similarly to geometric changes, the areal systolic deformation 
decreased with increasing RF energy (Fig. 9E), due primarily to shrinkage in the 
circumferential direction. Additionally, there was a consistent trend of decreasing axial 
systolic deformation in both the circumferential and radial directions with increasing RF 
energy (Fig. 9F), although the changes in the radial direction were not significant.  
 
Temperature Distribution 
Leaflet tissue > 65°C was quantified to identify the area of the leaflet exposed to 
temperatures that cause thermal damage to collagen. The area > 65°C was found to 
increase with increasing RF energy, from 0.51 ± 0.13 cm2 to 1.9 ± 0.13 cm2 at energies 
of 350 J and 1250 J, respectively (Fig. 10A). The tissue area below 0°C was used to 
determine the degree of cryo-anchoring present during ablation and was approximately 
0.14 ± 0.05 cm2 at the end of the 1250 J ablations. For comparison, the area of the cryo-
anchor in contact with the leaflet during the procedure is approximately 0.12 cm2. 
Thermal contours at the end of each treatment indicate distinct regions of cryo-anchoring 
and tissue ablation (Fig. 10B). The thermal contour plots at the end of the 350 J 
treatment shows minimal tissue > 65°C, while the majority of the leaflet tissue is > 65°C 
in the 1250 J treatment.  
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Figure 10. Infrared Thermal Imaging. (A) Tissue areas heated to > 65°C by RF 
ablation (red bars) and cooled to < 0°C by cryo-anchoring, as measured at the end of 
treatment. + Significant increase vs. 350 J (p<0.005) and ** significant increase vs. 850 J 
(p<0.05). (B) Infrared thermal contour images prior to (time = 0) and following RF 
ablations of 350 J, 850 J, and 1250 J RF, with simultaneous cryo-anchoring. 
 
 
Anchor Strength 
Following cryo-anchoring for 10 s, anchor strength was found to be 1020 ± 23 
kPa (Fig. 11). As expected, application of RF ablation at 50 W for 10 s with cryo-
anchoring reduced the anchor strength significantly (p<0.005) to 668 ± 79 kPa; however, 
the adherence is still robust.  
 
Figure 11. Cryo-Anchor Strength. Cryo-anchor strength following 10 s of attachment 
(blue bar) and 10 s of cryo-anchoring with 50 W of RF ablation (red bar). + Significant 
decrease vs. cryo only (p<0.005). 
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Discussion 
We have previously shown that RF ablation directionally alters MV leaflet 
geometry and compliance.36 The therapeutic effect of our percutaneous treatment 
strategy is to restore competence to diseased or prolapsed MV leaflets by reducing 
leaflet size, and therefore, displacement of leaflets into the atrium during systole. 
However, any device that aims to percutaneously treat MVP must do so in a highly 
dynamic mechanical environment. Additionally, due to the high rate of blood flow across 
the MV and the resulting potential for heat convection, application of RF energy must be 
performed with the RF electrode in direct contact with the target tissue. Thus, we have 
introduced cryo-anchoring as a means to potentially maintain direct catheter contact with 
a moving MV leaflet and to enhance stability during the procedure. During cryo-
anchoring, tissue is cooled to < 0°C, which interferes with the resistive heating that is the 
therapeutic mechanism behind RF ablation. However, due to the small size of MV 
leaflets, cryo-anchoring must be utilized in close proximity to the RF electrode. In this 
study, we demonstrate the effects of using two competing energy modalities and the 
feasibility of RF ablation performed with cryo-anchoring.  
 
More RF Energy Required with Cryo-Anchoring 
Biaxial mechanical data following treatment with the catheter prototype 
demonstrates that RF ablation remains a valid therapy, even with sub-freezing 
temperatures on the cryo-anchor in close proximity on the MV leaflet (Fig. 9). To 
determine the extent to which cryo-anchoring reduces the biomechanical effects of RF 
ablation, we re-analyzed previous biaxial data from treatment with a commercially 
available RF catheter (7F, Blazer II, Boston Scientific) without cryo-anchoring,36 plotting 
the % change in areal systolic deformation alongside our data presented here (Fig. 12). 
While RF ablation with cryo-anchoring altered unloaded MV leaflet geometry and  
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Figure 12. Biomechanical Changes With and Without Cryo-Anchoring. % change in 
areal systolic deformation with RF ablation alone (black bars) 36 and RF + cryo-
anchoring (gray bars), demonstrating that more RF energy is needed when cryo-
anchoring is utilized to produce the same therapeutic effect as RF ablation alone. 
 
 
deformation at systolic loading, it took significantly more energy versus RF ablation 
alone to produce the same effect. Previous treatments using the commercially available 
RF catheter reduced areal systolic deformation by approximately 25% when 350 J of 
energy was applied at a power of 25 W.36 In treatments utilizing cryo-anchoring, areal 
systolic deformation decreased by only 2.8 ± 0.6% under the same RF conditions. 
However, when 1250 J of energy was applied at a power of 50 W, our catheter prototype 
was able to produce changes similar to the commercially available catheter at 350 J. 
These results indicate that even though RF power must be increased significantly when 
cryo-anchoring is used, the catheter prototype can still achieve the same therapeutic 
effect.  
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Thermally-Related Collagen Contracture 
RF ablation introduces both geometric and biomechanical changes in MV 
leaflets; specifically, changes in areal systolic deformation are primarily due to length 
changes in the circumferential direction (Fig. 9D). This shortening of the collagen fibers 
in the circumferential direction is due to thermal rupture of heat-sensitive bonds and 
uncoiling of the collagen triple helix. This uncoiling of collagen fibers and transition from 
a crystalline state to a random coil is responsible for collagen shortening, and 
transmission electron microscopy of collagenous tissues treated with RF ablation show 
collagen fibrils that increase in average diameter with increasing RF power.30 
Additionally, aligned collagen fibers fuse together in the orthogonal directions after 
treatment with RF ablation,29-30 leading to modest changes seen in the radial direction 
here (Fig. 9D). Therefore, the use of a cryo-anchor for stability during the RF ablation 
procedure reduces the therapeutic effect of RF energy, but this effect can be mitigated 
by increasing RF power. 
 
Heat Distribution of RF Ablation with Cryo-Anchoring 
In addition to determining biomechanical changes induced by RF ablation, we 
have analyzed the temperature distribution resulting from combined RF ablation with 
cryo-anchoring. Estimates for the onset of unwinding of the collagen triple helix vary and 
have been determined to be approximately 60°C in the bovine joint capsule34 and 67.1°C 
in the bovine mitral valve.2 Thus, we used 65°C as a threshold for permanent collagen 
denaturation and determined the area of tissue heated above this temperature. IR 
imaging reveals that while there is a distinct region of cryo-anchoring present through 
the full thickness of the leaflet, which stays relatively consistent across all RF energies, 
heating due to RF ablation dominates the leaflet temperature distribution. As a result, full 
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thickness temperatures < 0°C are confined to an area slightly larger than the cryo-
anchor attachment area. Because thermal damage to the collagen matrix forms the 
basis of mechanical damage, we hypothesized that the tissue area heated above 65°C 
would correlate with changes in areal systolic deformation (Fig. 13). Indeed, this 
correlation is evident when % change in areal systolic deformation is plotted against 
tissue area above 65°C, demonstrating that biomechanical changes may be directly 
related to the amount of thermal tissue damage.  
 
Figure 13. Biomechanical Changes and Area of Tissue Heating. % change in areal 
systolic deformation vs. tissue area > 65°C, as determined by processing of IR thermal 
images at the end of ablation. 
Model fit: -  
 
 
Cryo-Anchor Attachment to MV Leaflets 
Testing of the anchor strength of the cryo-anchor revealed that this attachment is 
sufficient to maintain contact, even with RF ablation, with stationary MV leaflets. While 
there are currently no direct estimates for the anchor strength required to maintain 
attachment to the MV during the cardiac cycle, one estimate can be made based on the 
atrial pressure during MV opening. Because the proposed catheter treatment involves 
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access to the MV via the left atrium, and the peak atrial pressure is a representation of 
the force required to open the MV, this is an estimate for the minimum attachment force 
required to maintain adherence. Peak atrial pressure in normally functioning hearts is 
typically below 20 mmHg,14 or about 2.7 kPa. Thus, even if a much higher estimate for 
the atrial pressure is chosen, this value is considerably lower than the approximately 668 
kPa of anchor strength recorded at 10 s of the 50 W RF ablation. Additionally, we 
speculate that cryo-anchoring and ablation of MV leaflets will occur with the MV kept 
partially open, with one leaflet kept anchored and the other moving freely. This may 
further reduce the force required to maintain cryo-anchoring. 
 
Study Limitations 
The data presented here indicate that RF ablation performed with cryo-anchoring 
alters MV leaflet geometry and deformation in vitro; however, there are several 
limitations to this study. First, all treatments were performed on stationary leaflets in 
vitro. While this ensures robust delivery of RF energy, it is not realistic, particularly with 
regards to the anchor strength studies. Further work must be performed to verify the 
feasibility of cryo-anchoring on moving MV leaflets, both in vitro and in vivo. Additionally, 
ablations in the biomechanical and thermal imaging studies were performed on leaflets 
with the saline bath lowered, such that the maximum amount of RF energy would 
penetrate the leaflets. This provides a much more accurate measurement of the total 
energy delivered to the leaflet, but the in vivo environment is much more dynamic. Due 
to convective blood flow, in vivo treatments will require additional or prolonged RF 
energy delivery in order to produce the same biomechanical alterations, as 
demonstrated in a feasibility study utilizing a canine model.43 Finally, these studies were 
performed on healthy porcine MV leaflets. It is unknown how leaflets with MVP might 
respond to RF ablation, due to their disorganized collagen architecture.  
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Design Considerations for In Vivo Translation 
In light of the results from this study, and what is previously known regarding RF 
ablation, we have identified several design considerations for in vivo translation of our 
combined RF ablation and cryo-anchoring catheter. First, we demonstrated in vitro that 
RF energy must be increased when used in conjunction with cryo-anchoring in order to 
achieve a similar therapeutic effect of RF alone. Because our biaxial mechanical 
analysis was performed on leaflets treated while only partially submerged, heat 
dissipation will likely increase when treatment is performed in vivo, due to the 
surrounding hemodynamic environment. Thus, RF energy delivery will likely need to be 
increased in a similar manner and this will likely be accomplished by increasing either 
RF power or application time. Similarly, through placement in a dynamic hemodynamic 
environment and increases in application of RF energy, cryo-anchor strength may be 
reduced at the current liquid nitrogen delivery protocol, and liquid nitrogen delivery may 
need to be increased by increasing vacuum pressure and delivery time to compensate. 
Also, in order to decrease the amount of RF energy lost to the blood stream, RF 
electrode placement can be re-designed to allow for more direct delivery to the leaflets. 
One possible improvement is to replace the current, singular RF electrode, which 
encircles the entire 360º outer circumference of the catheter shaft, with three separate 
RF electrodes that are approximately 120º of the circumference and are insulated from 
each other. By having three separate electrodes, RF energy can be delivered to the 
electrode in direct contact with the leaflet, ensuring that the majority of RF energy enters 
the leaflet, as opposed to the bloodstream. These, and other potential modifications, will 
likely be necessary to translate this strategy into an integrated catheter that will be 
successful in vivo.  
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Conclusions 
In this study, we demonstrate that RF ablation with a cryo-anchor may provide an 
alternative percutaneous treatment strategy for MVP. While it was previously shown that 
RF ablation alone reduces MV leaflet size, we have demonstrated the feasibility of cryo-
anchoring as a stability technique for secure attachment of a catheter to a MV leaflet. 
Additionally, cryo-anchoring may have possible uses in other applications involving RF 
ablation or in more general percutaneous catheters as a mechanism to enhance stability 
and improve catheter contact in complex anatomies or hard-to-reach sites. Cryo-
anchoring may be a particularly effective strategy in improving catheter stability during 
treatment of cardiac arrhythmias, given the dynamic environment of the heart. While we 
found here that cryo-anchoring reduces the effect of RF ablation, these effects can be 
mitigated by increasing RF power and duration. These in vitro results indicate that RF 
ablation with simultaneous cryo-anchoring reduces MV leaflet size and may be a viable 
clinical strategy for percutaneous treatment of myxomatous MVP.  
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CHAPTER III 
 
CONCLUSIONS AND FUTURE WORK 
 
Conclusions 
 The result from this work is a demonstration of the feasibility of RF ablation with 
cryo-anchoring to reduce MV leaflet size. Additionally, this geometric shrinkage is 
maintained throughout the loading cycle, indicating a reduction in leaflet size at 
maximum systolic load when leaflets should be fully closed and without mitral 
regurgitation. Infrared thermal imaging revealed the feasibility of using radiofrequency 
ablation with cryo-anchoring in close proximity, on the same leaflet, and anchor strength 
demonstrated that cryo-anchor strength remains robust during application of RF energy. 
Future Work 
 Feasibility of the combined radiofrequency ablation and cryo-anchoring approach 
has been demonstrated in vitro on stationary, excised MV leaflets. While this represents 
a substantial step forward, this approach has yet to be tested on a moving, functioning 
mitral valve and is an important milestone before in vivo animal testing can begin. The 
first step towards testing on whole, functioning mitral valves is to use the results of these 
experiments to develop a new catheter prototype that can be used for further in vitro 
testing, as well as in vivo testing in the future. The current prototype is large and bulky, 
with many components – including the RF electrode and thermocouple wires – housed 
external to the catheter. Including these components inside the lumen of the catheter will 
enhance the range of tests which can be performed. Additionally, liquid nitrogen is 
currently pumped out of a cryo canister under a laboratory house vacuum, which limits 
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the length of the catheter and limits its mobility. Improving the pumping system used to 
deliver liquid nitrogen to the catheter tip will improve its range and enhance control over 
the amount of liquid nitrogen delivery.  
 Once these improvements have been made to the catheter prototype, further in 
vitro experiments can be performed on whole, intact mitral valves. A left heart flow 
simulator is currently being developed to replicate blood flow through the left side of the 
heart (Fig. 14).  
 
Figure 14. Left Heart Flow Simulator Design. A) Schematic representation of the left 
heart flow simulator currently in development showing the flow probe and pressure 
transducer to measure performance of an excised, porcine mitral valve following 
treatment with catheter prototypes. B) Solid model of the ventricle and atrium, showing 
attachment of excised mitral valves and catheter entry. 
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The left heart flow simulator has the capability to integrate excised porcine mitral valves 
within the device by suturing the mitral annulus to a flexible membrane at the ventricle-
atrium interface and attaching the papillary muscles to adjustable holders within the 
ventricle (Fig. 15). 
 
Figure 15. Left Heart Flow Simulator Testing. A) Testing of the left heart flow 
simulator, indicating placement of the ventricle, atrium, and pump. B) Papillary muscle 
holders and a mechanical valve indicating the attachment site for excised porcine mitral 
valves. 
 
The ability to place an intact, excised MV inside a left heart simulator will allow direct 
measurement of changes to pressure and flow across the MV as a result of treatment 
with combined RF ablation and cryo-anchoring prototypes. The use of the left heart flow 
simulator will allow testing of catheter prototypes and refinement of control over RF 
energy and cryo-anchor delivery in a well-controlled environment that mimics the 
hemodynamics of the heart. Testing with the left heart flow simulator will provide 
feedback on the efficacy of catheter prototypes that will be used to improve catheter 
design and determine the ideal treatment protocols prior to in vivo animal testing. The 
ultimate goal of this bench-top strategy is to further validate the feasibility of combined 
RF ablation and cryo-anchoring as a technique to percutaneously treat MVP and to 
A B
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determine the therapeutic window of treatment with RF energy prior to testing in an 
animal model. 
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